Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to assess the effect of rosiglitazone on bioavailable, free and total testosterone levels in hypogonadal men with type 2 diabetes. Sixteen type 2 diabetic men with hypogonadism were studied before and after administration of rosiglitazone (8 mg/day) for six months, with assessments performed every two months on two consecutive days. We measured testosterone and sex hormone binding globulin (SHBG), visceral adiposity, high-sensitivity CRP (hs-CRP), lipids, microalbuminuria and blood pressure. There was a significant increase in free (p=0.01), bioavailable (p=0.007) and total testosterone (p=0.002), as well as SHBG (p=0.03) levels, with rosiglitazone treatment. Waist circumference and waist/hip ratio decreased with the improvement in insulin sensitivity and glycaemic control (p=0.01). There was also a significant reduction in hs-CRP (p=0.02) and urinary albumin excretion. No significant effect on blood pressure or the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (LDL to HDL) was seen. In conclusion, the insulin-sensitiser rosiglitazone increases bioavailable, free and total testosterone and SHBG levels in hypogonadal men with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“Testosterone replacement in hypogonadal men with diabetes improves insulin sensitivity, glycaemic control and waist circumference.(15) The beneficial effects of rosiglitazone on testosterone and visceral adiposity were associated with improved glycaemic control, decreased urinary albumin excretion and hs-CRP.”
BackgroundSelf-citationValidation of a screening questionnaire for androgen deficiency in aging males
Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., & Perry, H. M. (2000) · Metabolism · doi:10.1053/meta.2000.8625 · Cited by 662
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631 · cited 1×
“This is confirmed by studies that have shown approximately one third of men with type 2 diabetes were hypogonadal by FT assayed by equilibrium dialysis and BT measured by ammonium sulphate precipitation.(6,7) Rosiglitazone, as in this study, is known to increase the BMI.”
ResultStellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.490 · Cited by 618
Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes
Kapoor, D., Aldred, H., Clark, S., Channer, K. S., & Jones, T. H. (2007) · Diabetes Care · doi:10.2337/dc06-1426 · Cited by 493
Self-citationMårin, P., Odén, B., & Björntorp, P. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.1.7829619 · Cited by 332 · cited 1×
“The rising level of testosterone then inhibits lipoprotein lipase enzyme activity in visceral fat, reducing fatty acid uptake and decreasing visceral adipose tissue mass.(14) This in turn results in further increases in testosterone concentrations.”
BackgroundHaffner, S. M., Shaten, J., Stem, M. P., Smith, G. D., Kuller, L., & MRFIT Research Group (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008832 · Cited by 320
Androgens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Self-citationTestosterone concentrations in women and men with NIDDM
Andersson, B., Märin, P., Lissner, L., Vermeulen, A., & Björntorp, P. (1994) · Diabetes Care · doi:10.2337/diacare.17.5.405 · Cited by 268
Cited by
Steroidogenesis in the Fetal Testis and Its Susceptibility to Disruption by Exogenous Compounds
Scott, H. M., Mason, J. I., & Sharpe, R. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0016 · Cited by 350
Novel insights in SHBG regulation and clinical implications
Simó, R., Sáez-López, C., Barbosa-Desongles, A., Hernández, C., & Selva, D. M. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.05.001 · Cited by 335
Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity
Dandona, P., & Dhindsa, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2724 · Cited by 313
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
Rao, P. M., Kelly, D. M., & Jones, T. H. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.122 · Cited by 292
Self-citationSex Hormone-Binding Globulin Gene Expression and Insulin Resistance
Winters, S. J., Gogineni, J., Karegar, M., Scoggins, C., Wunderlich, C. A., Baumgartner, R., & Ghooray, D. T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2640 · Cited by 79
Metadata
- Authors
- Kapoor, D., Channer, K. S., & Jones, T. H.
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2008-01-01
- Volume
- 5
- Issue
- 2
- Pages
- 135-137
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- OpenAlex
- W2128642380
- Cited by
- 58
- References
- 12
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.